ArticleBMJ mental health2025
Identifying modifiable factors and their joint associations on late-onset schizophrenia risk in the UK Biobank: a prospective exposure-wide association study.
Article in BMJ mental health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundOne in four cases of schizophrenia begins in late life, resulting in high unemployment and reduced life expectancy. However, knowledge of the modifiable risk factors for late-onset schizophrenia and their combined effects is limited.
aimsTo identify modifiable risk factors for late-onset schizophrenia and estimate their joint disease risk effects.
methodsThis prospective cohort study using UK Biobank data included 482 708 participants without late-onset schizophrenia at baseline, followed up for a mean of 14.36 years. We conducted an exposure-wide association study of 232 potentially modifiable factors linked to late-onset schizophrenia risk. Late-onset schizophrenia is diagnosed using ICD-10 (International Classification of Diseases, 10th Revision) criteria. Cox proportional hazard models identified significant factors across six domains: lifestyle, environment, medical history, physical measures, mental health and socioeconomic status (SES). Domain-specific weighted scores were calculated from Cox model coefficients and stratified into tertiles (favourable, intermediate, unfavourable) for risk assessment. Population attributable fractions (PAFs) quantified prevention potential.
resultsDuring follow-up, 1276 participants developed late-onset schizophrenia. We identified 109 significant potentially modifiable factors, with intellectual disability (HR 35.15, 95% CI 11.23 to 110.09), manic episode (HR 33.14, 95% CI 21.16 to 51.90) and bipolar affective disorder (HR 32.91, 95% CI 27.07 to 40.01) showing the strongest risks, while higher household income (>£100 000: HR 0.14, 95% CI 0.09 to 0.22), regular friends/family visits (HR 0.23, 95% CI 0.18 to 0.28) and higher hand grip strength (HR 0.35, 95% CI 0.29 to 0.44) showed the strongest protection. PAF estimations indicated that shifting individuals from unfavourable to intermediate/favourable risk profiles could prevent 71.3% (95% CI 71.2% to 71.4%) of late-onset schizophrenia cases, mainly from mental health (25.1%, 95% CI 25.0% to 25.2%), medical history (13.6%, 95% CI 13.5% to 13.7%) and SES domain (11.2%, 95% CI 11.1% to 11.3%); shifting individuals from intermediate/unfavourable risk profiles to favourable could prevent 89.2% of cases.
conclusionsA substantial proportion of late-onset schizophrenia risk appears modifiable, with mental health and medical history as key contributors. Physical health and natural environment exposure provided protective benefits. Findings supported integrating clinical interventions and structural changes addressing socioeconomic and environmental factors to reduce late-onset schizophrenia burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.